Company: MDCXW
Filing Date: 2025-05-13
Form Type: 424B3
Source: 0001062993-25-009166
Chunk: 26

Company: Medicus Pharma Ltd.
Filing Date: 2025-05-13
Form: 424B3
Chunk 26
---
 reporting to remediate any control deficiencies. These measures include (i) designing and implementing procedures to improve the precision and quality in the review of materials used in financial reporting, and (ii) designing and implementing policies related to our overall IT system environment. Changes in Internal Control over Financial Reporting There were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) during the most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. 24 PART II - OTHER INFORMATION Item 1. Legal Proceedings There is no material litigation, arbitration or governmental proceeding currently pending against us or any members of our management team in their capacity as such, and we and the members of our management team have not been subject to any such proceeding in the 12 months preceding the date hereof. Item 1A. Risk Factors Factors that could cause our actual results to differ materially from those in this Quarterly Report on Form 10-Q include the risk factors described in the Company's 2024 Annual Report . Any of these risk factors could result in a significant or material adverse effect on the Company's business, financial condition and/or results of operations. Additional risk factors not presently known to us or that we currently deem immaterial may also impair our business or results of operations. As of the date of this Quarterly Report on Form 10-Q, there have been no material changes to the risk factors disclosed in the 2024 Annual Report. Item 2. Unregistered Sales of Equity Securities and Use of Proceeds As previously disclosed, on February 10, 2025, the Company entered into the SEPA with Yorkville. As consideration for Yorkville's commitment to purchase the common shares pursuant the SEPA, the Company paid Yorkville a structuring fee in the amount of $25,000 and issued to Yorkville 105,840 common shares, which common shares were issued pursuant to the exemption provided by Section 4(a)(2) of the Securities Act. As previously disclosed, on March 10, 2025, the Company completed an offering of 1,490,000 units, each unit consisting of one common share and one warrant to purchase one common share at an exercise price of $2.80 with an expiration date of March 10, 2030 (each a "Regulation A Warrant") pursuant to Tier II of Regulation A under the Securities Act ("